Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Fluidigm's OpenApp Program for C1 Single-Cell Platform

Premium

Fluidigm last week launched the C1 OpenApp Program, giving researchers the ability to create and share new single-cell applications on the C1 Single-Cell Auto Prep System.

The C1 system allows researchers to, in one integrated workflow, isolate, stain, lyse, and process 96 live cells in less than 24 hours for downstream analyses of cellular heterogeneity. With the new OpenApp Program, users can modify or develop new scripts for single-cell research using the C1 system.

Two key elements of the new program are the C1 Script Builder software, available now, and the C1 Script Hub, expected to be available in late 2014. The C1 Script Builder is a standalone desktop software with which users can create custom scripts for their C1 Open App IFC and import them to their C1 system to run their script. The C1 Script Hub is a web portal through which Fluidigm will make third-party protocols available to the C1 user base.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.